Annual Accounts Receivable
$7.11 B
-$959.00 M-11.89%
31 December 2023
Summary:
Novartis AG annual accounts receivable is currently $7.11 billion, with the most recent change of -$959.00 million (-11.89%) on 31 December 2023. During the last 3 years, it has fallen by -$1.11 billion (-13.51%). NVS annual accounts receivable is now -31.15% below its all-time high of $10.32 billion, reached on 31 December 2011.NVS Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$7.97 B
-$262.00 M-3.18%
30 September 2024
Summary:
Novartis AG quarterly accounts receivable is currently $7.97 billion, with the most recent change of -$262.00 million (-3.18%) on 30 September 2024. Over the past year, it has increased by +$1.15 billion (+16.82%). NVS quarterly accounts receivable is now -27.02% below its all-time high of $10.91 billion, reached on 30 June 2011.NVS Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVS Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -11.9% | +16.8% |
| 3 y3 years | -13.5% | -4.9% |
| 5 y5 years | -18.6% | +1.8% |
NVS Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -13.5% | at low | -13.4% | +16.8% |
| 5 y | 5 years | -18.6% | at low | -13.4% | +16.8% |
| alltime | all time | -31.1% | +120.2% | -27.0% | +146.8% |
Novartis AG Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $7.97 B(-3.2%) |
| June 2024 | - | $8.23 B(+4.9%) |
| Mar 2024 | - | $7.84 B(+10.3%) |
| Dec 2023 | $7.11 B(-11.9%) | $7.11 B(+4.2%) |
| Sept 2023 | - | $6.82 B(-25.8%) |
| June 2023 | - | $9.20 B(+3.1%) |
| Mar 2023 | - | $8.92 B(+10.5%) |
| Dec 2022 | $8.07 B(+0.8%) | $8.07 B(-4.2%) |
| Sept 2022 | - | $8.42 B(-2.6%) |
| June 2022 | - | $8.64 B(+2.8%) |
| Mar 2022 | - | $8.41 B(+5.0%) |
| Dec 2021 | $8.01 B(-2.6%) | $8.01 B(-4.4%) |
| Sept 2021 | - | $8.38 B(-0.3%) |
| June 2021 | - | $8.40 B(+1.6%) |
| Mar 2021 | - | $8.27 B(+0.6%) |
| Dec 2020 | $8.22 B(-1.0%) | $8.22 B(+1.8%) |
| Sept 2020 | - | $8.07 B(+5.6%) |
| June 2020 | - | $7.64 B(-10.5%) |
| Mar 2020 | - | $8.54 B(+2.9%) |
| Dec 2019 | $8.30 B(-4.9%) | $8.30 B(+6.1%) |
| Sept 2019 | - | $7.83 B(-1.8%) |
| June 2019 | - | $7.97 B(+4.7%) |
| Mar 2019 | - | $7.61 B(-12.8%) |
| Dec 2018 | $8.73 B(+1.5%) | $8.73 B(+1.7%) |
| Sept 2018 | - | $8.59 B(-2.5%) |
| June 2018 | - | $8.80 B(-1.3%) |
| Mar 2018 | - | $8.92 B(+3.7%) |
| Dec 2017 | $8.60 B(+4.9%) | $8.60 B(+1.4%) |
| Sept 2017 | - | $8.48 B(+1.2%) |
| June 2017 | - | $8.38 B(+1.8%) |
| Mar 2017 | - | $8.23 B(+0.4%) |
| Dec 2016 | $8.20 B(+0.3%) | $8.20 B(-4.0%) |
| Sept 2016 | - | $8.55 B(-0.7%) |
| June 2016 | - | $8.61 B(+1.7%) |
| Mar 2016 | - | $8.46 B(+3.5%) |
| Dec 2015 | $8.18 B(-1.1%) | $8.18 B(-3.7%) |
| Sept 2015 | - | $8.49 B(-2.9%) |
| June 2015 | - | $8.75 B(-0.5%) |
| Mar 2015 | - | $8.79 B(+6.3%) |
| Dec 2014 | $8.28 B(-16.4%) | $8.28 B(-6.6%) |
| Sept 2014 | - | $8.86 B(-5.5%) |
| June 2014 | - | $9.37 B(-9.2%) |
| Mar 2014 | - | $10.32 B(+4.3%) |
| Dec 2013 | $9.90 B(-1.5%) | $9.90 B(-5.7%) |
| Sept 2013 | - | $10.50 B(-2.7%) |
| June 2013 | - | $10.79 B(+2.9%) |
| Mar 2013 | - | $10.48 B(+4.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $10.05 B(-2.6%) | $10.05 B(-4.4%) |
| Sept 2012 | - | $10.52 B(+0.3%) |
| June 2012 | - | $10.49 B(-1.1%) |
| Mar 2012 | - | $10.61 B(+2.7%) |
| Dec 2011 | $10.32 B(+4.6%) | $10.32 B(-3.6%) |
| Sept 2011 | - | $10.70 B(-1.9%) |
| June 2011 | - | $10.91 B(+0.5%) |
| Mar 2011 | - | $10.86 B(+10.0%) |
| Dec 2010 | $9.87 B(+18.8%) | $9.87 B(-5.0%) |
| Sept 2010 | - | $10.39 B(+33.3%) |
| June 2010 | - | $7.80 B(+0.3%) |
| Mar 2010 | - | $7.77 B(-6.5%) |
| Dec 2009 | $8.31 B(+18.3%) | $8.31 B(+6.3%) |
| Sept 2009 | - | $7.82 B(+9.1%) |
| June 2009 | - | $7.17 B(+6.2%) |
| Mar 2009 | - | $6.75 B(-3.9%) |
| Dec 2008 | $7.03 B(+5.7%) | $7.03 B(-3.1%) |
| Sept 2008 | - | $7.25 B(+1.5%) |
| June 2008 | - | $7.14 B(+3.8%) |
| Mar 2008 | - | $6.88 B(+3.5%) |
| Dec 2007 | $6.65 B(+7.9%) | $6.65 B(-2.4%) |
| Sept 2007 | - | $6.81 B(+9.3%) |
| June 2007 | - | $6.23 B(-1.9%) |
| Mar 2007 | - | $6.35 B(+3.1%) |
| Dec 2006 | $6.16 B(+15.3%) | $6.16 B(+1.2%) |
| Sept 2006 | - | $6.09 B(+3.4%) |
| June 2006 | - | $5.88 B(+11.2%) |
| Mar 2006 | - | $5.29 B(-1.0%) |
| Dec 2005 | $5.34 B(+10.1%) | $5.34 B(+4.0%) |
| Sept 2005 | - | $5.14 B(+0.9%) |
| June 2005 | - | $5.09 B(+4.8%) |
| Mar 2005 | - | $4.86 B(+0.1%) |
| Dec 2004 | $4.85 B(+10.9%) | $4.85 B(+8.0%) |
| Sept 2004 | - | $4.49 B(+0.2%) |
| June 2004 | - | $4.48 B(+3.6%) |
| Mar 2004 | - | $4.33 B(-1.1%) |
| Dec 2003 | $4.38 B(+18.4%) | $4.38 B(+2.9%) |
| Sept 2003 | - | $4.25 B(-0.1%) |
| June 2003 | - | $4.26 B(+8.4%) |
| Mar 2003 | - | $3.93 B(+6.2%) |
| Dec 2002 | $3.70 B(+14.5%) | $3.70 B(+0.9%) |
| Sept 2002 | - | $3.66 B(+1.4%) |
| June 2002 | - | $3.61 B(+11.9%) |
| Dec 2001 | $3.23 B(-1.4%) | $3.23 B(-31.7%) |
| June 2001 | - | $4.73 B(+44.4%) |
| Dec 2000 | $3.27 B(-26.0%) | $3.27 B |
| Dec 1999 | $4.42 B(+4.6%) | - |
| Dec 1998 | $4.23 B | - |
FAQ
- What is Novartis AG annual accounts receivable?
- What is the all time high annual accounts receivable for Novartis AG?
- What is Novartis AG annual accounts receivable year-on-year change?
- What is Novartis AG quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Novartis AG?
- What is Novartis AG quarterly accounts receivable year-on-year change?
What is Novartis AG annual accounts receivable?
The current annual accounts receivable of NVS is $7.11 B
What is the all time high annual accounts receivable for Novartis AG?
Novartis AG all-time high annual accounts receivable is $10.32 B
What is Novartis AG annual accounts receivable year-on-year change?
Over the past year, NVS annual accounts receivable has changed by -$959.00 M (-11.89%)
What is Novartis AG quarterly accounts receivable?
The current quarterly accounts receivable of NVS is $7.97 B
What is the all time high quarterly accounts receivable for Novartis AG?
Novartis AG all-time high quarterly accounts receivable is $10.91 B
What is Novartis AG quarterly accounts receivable year-on-year change?
Over the past year, NVS quarterly accounts receivable has changed by +$1.15 B (+16.82%)